D2S Pharma
ActiveActs, filings and financial milestones
Deadline for the 2026 accounts:
2026
20-02
financial year 2025 · abbreviated format · 20 days late
2025
07-01
financial year 2024 · abbreviated format
2024
09-02
financial year 2023 · abbreviated format · 9 days late
2023
30-06
Financial
Weakest financial yearnet €2,575 ▼79.1%
The net result drops to €2,575, the lowest from 2019 to 2025. It recovers the following year.
25-01
financial year 2022 · abbreviated format
2022
28-01
financial year 2021 · abbreviated format
2021
30-06
Financial
Highest result from 2019 to 2025net €191,036 ▲44.7%
The operating result of €257,327 and the net result of €191,036 are both a record.
30-06
Financial
Equity above €200,000equity €353,632 ▲117%
With a profit in every financial year since 2019, equity grows to €353,632.
27-01
financial year 2020 · abbreviated format
2020
30-06
Financial
Equity above €150,000equity €162,596 ▲431%
With a profit in every financial year since 2019, equity grows to €162,596.
2019
2018
10-01
financial year 2017 · micro format
2017
16-01
financial year 2016 · abbreviated format
Financial milestoneNBB filingFinancial milestones sit on the financial year-end date, not the filing date.
Sources:Publications in the Belgian Official GazetteFilings with the National Bank